Clinical Trials
14
Active:4
Completed:5
Trial Phases
5 Phases
Phase 1:1
Phase 2:2
Phase 3:2
+2 more phases
Drug Approvals
59
SFDA:35
NMPA:9
PHILIPPINES:8
+1 more agencies
Drug Approvals
Lanthanum Carbonate Chewable Tablets
- Product Name
- 碳酸镧咀嚼片
- Approval Number
- 国药准字HJ20240159
- Approval Date
- Dec 6, 2024
NMPA
Lanthanum Carbonate Chewable Tablets
- Product Name
- 碳酸镧咀嚼片
- Approval Number
- 国药准字HJ20240160
- Approval Date
- Dec 6, 2024
NMPA
Doxorubicin Hydrochloride Liposome Injection
- Product Name
- 盐酸多柔比星脂质体注射液
- Approval Number
- 国药准字HJ20240055
- Approval Date
- Jun 28, 2024
NMPA
Doxorubicin Hydrochloride Liposome Injection
- Product Name
- 盐酸多柔比星脂质体注射液
- Approval Number
- 国药准字HJ20240056
- Approval Date
- Jun 28, 2024
NMPA
Abiraterone Acetate Tablets
- Product Name
- 醋酸阿比特龙片
- Approval Number
- 国药准字HJ20233124
- Approval Date
- Feb 14, 2023
NMPA
Oseltamivir Phosphate Capsules
- Product Name
- 磷酸奥司他韦胶囊
- Approval Number
- 国药准字HJ20220024
- Approval Date
- Mar 29, 2022
NMPA
Oseltamivir Phosphate Capsules
- Product Name
- 磷酸奥司他韦胶囊
- Approval Number
- 国药准字HJ20220025
- Approval Date
- Mar 29, 2022
NMPA
Oseltamivir Phosphate Capsules
- Product Name
- 磷酸奥司他韦胶囊
- Approval Number
- 国药准字HJ20220023
- Approval Date
- Mar 29, 2022
NMPA
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Not Applicable
2 (25.0%)Phase 2
2 (25.0%)Phase 3
2 (25.0%)Phase 1
1 (12.5%)Phase 4
1 (12.5%)No trials found
News
NATCO Pharma's Mekaguda API Facility Receives FDA Establishment Inspection Report Following Successful Remediation
NATCO Pharma Limited received an Establishment Inspection Report (EIR) from the U.S. FDA for its Active Pharmaceutical Ingredient facility in Mekaguda, Hyderabad on July 24, 2025.